JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO.,LTD.

Financials Joincare Pharmaceutical Group Industry Co.,Ltd.

Equities

600380

CNE000001816

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
13.16 ^CNY	+1.46%		+4.94%	+5.87%

04-25	Joincare Pharmaceutical Group Industry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Joincare Pharma Says Flu Drug Phase 3 Trial Attains Primary Endpoint	MT

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	20,059	26,868	24,015	21,061	23,173	24,565	-	-
Enterprise Value (EV) ¹	20,059	26,868	24,015	21,061	23,173	24,565	24,565	24,565
P/E ratio	22.5 x	24.3 x	18.7 x	14.3 x	16.4 x	16.2 x	14 x	12.4 x
Yield	1.55%	1.08%	1.17%	1.59%	1.45%	1.41%	1.6%	1.67%
Capitalization / Revenue	1.67 x	1.99 x	1.51 x	1.23 x	1.39 x	1.41 x	1.3 x	1.23 x
EV / Revenue	1.67 x	1.99 x	1.51 x	1.23 x	1.39 x	1.41 x	1.3 x	1.23 x
EV / EBITDA	7.3 x	7.55 x	6.71 x	4.91 x	5.12 x	8.38 x	7.15 x	6.45 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	1.94 x	2.45 x	2.05 x	1.66 x	1.69 x	1.64 x	1.5 x	1.37 x
Nbr of stocks (in thousands)	1,938,033	1,931,529	1,870,352	1,865,499	1,864,280	1,866,635	-	-
Reference price ²	10.35	13.91	12.84	11.29	12.43	13.16	13.16	13.16
Announcement Date	20-04-10	21-03-30	22-03-30	23-04-10	24-04-02	-	-	-

¹CNY in Million²CNY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	11,980	13,522	15,904	17,143	16,646	17,364	18,968	19,978
EBITDA ¹	2,749	3,559	3,578	4,285	4,529	2,930	3,436	3,806
EBIT ¹	2,187	2,973	2,983	3,480	3,507	3,646	4,210	4,812
Operating Margin	18.26%	21.99%	18.76%	20.3%	21.07%	21%	22.2%	24.08%
Earnings before Tax (EBT) ¹	2,178	2,950	2,952	3,456	3,466	3,622	4,186	4,774
Net income ¹	894.3	1,120	1,328	1,503	1,443	1,521	1,743	1,984
Net margin	7.47%	8.29%	8.35%	8.77%	8.67%	8.76%	9.19%	9.93%
EPS ²	0.4607	0.5728	0.6858	0.7921	0.7565	0.8133	0.9367	1.065
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	0.1600	0.1500	0.1500	0.1800	0.1800	0.1850	0.2100	0.2200
Announcement Date	20-04-10	21-03-30	22-03-30	23-04-10	24-04-02	-	-	-

¹CNY in Million²CNY

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	8.98%	10.4%	11.5%	12.2%	11%	10.3%	10.8%	11%
ROA (Net income/ Total Assets)	-	4.18%	4.48%	4.5%	4%	5.33%	5.57%	6.4%
Assets ¹	-	26,798	29,630	33,417	36,047	28,519	31,310	30,992
Book Value Per Share ²	5.340	5.680	6.250	6.800	7.370	8.010	8.750	9.600
Cash Flow per Share ²	1.190	1.550	1.320	2.060	2.110	2.510	2.090	2.110
Capex ¹	701	781	1,512	1,145	1,115	913	1,116	975
Capex / Sales	5.85%	5.78%	9.51%	6.68%	6.7%	5.26%	5.88%	4.88%
Announcement Date	20-04-10	21-03-30	22-03-30	23-04-10	24-04-02	-	-	-

¹CNY in Million²CNY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Joincare Pharmaceutical Group Industry Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.16 CNY

Average target price

14.7 CNY

Spread / Average Target

+11.70%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JOINCARE PHARMACEUTICAL GROUP INDUSTRY CO.,LTD.	+5.87%	3.35B
ELI LILLY AND COMPANY	+31.06%	682B
NOVO NORDISK A/S	+30.35%	586B
JOHNSON & JOHNSON	-3.42%	364B
MERCK & CO., INC.	+18.02%	327B
ABBVIE INC.	+4.27%	285B
ASTRAZENECA PLC	+15.53%	240B
NOVARTIS AG	+10.16%	209B
ROCHE HOLDING AG	-8.14%	203B
AMGEN INC.	+8.12%	165B

Other Pharmaceuticals